MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zennadi, Rahima ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; HYDROXYUREA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RDEA 119; SELUMETINIB; TRAMETINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE COUNT; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; SICKLE CELL; SICKLE CELL ANEMIA; UMBILICAL VEIN ENDOTHELIAL CELL; ANEMIA, SICKLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL ADHESION; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; METABOLISM; NUDE MOUSE; PATHOLOGY; VASCULAR DISEASES;

ADULT; ANEMIA, SICKLE CELL; ANIMALS; CELL ADHESION; DISEASE MODELS, ANIMAL; ERYTHROCYTE AGGREGATION; ERYTHROCYTES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE INHIBITORS; VASCULAR DISEASES;

EID: 84908178939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110306     Document Type: Article

References (52)

1. De Castro LM, Zennadi R, Jonassaint JC, Batchvarova M, Telen MJ (2012) Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci 5: 437-444.
2. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH (1980) Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 302: 992-995.
3. Solovey AA, Solovey AN, Harkness J, Hebbel RP (2001) Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97: 1937-1941.
4. Hebbel RP (2008) Adhesion of sickle red cells to endothelium: myths and future directions. Transfus Clin Biol 15: 14-18.
5. Siciliano A, Malpeli G, Platt OS, Lebouef C, Janin A, et al. (2011) Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. Haematologica 96: 24-32.
6. Sabaa N, de Franceschi L, Bonnin P, Castier Y, Malpeli G, et al. (2008) Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 118: 1924-1933.
7. Ballas SK, Smith ED (1992) Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 79: 2154-2163.
8. Billett HH, Kim K, Fabry ME, Nagel RL (1986) The percentage of dense red cells does not predict incidence of sickle cell painful crisis. Blood 68: 301-303.
9. Kaul DK, Chen D, Zhan J (1994) Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 83: 3006-3017.
10. Kaul DK, Fabry ME, Nagel RL (1986) Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood 68: 1162-1166.
11. Lawrence C, Fabry ME, Nagel RL (1985) Red cell distribution width parallels dense red cell disappearance during painful crises in sickle cell anemia. J Lab Clin Med 105: 706-710.
12. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, et al. (2001) Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 286: 2099-2106.
13. Hines PC, Zen Q, Burney SN, Shea DA, Ataga KI, et al. (2003) Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 101: 3281-3287.
14. Zennadi R, Hines PC, De Castro LM, Cartron JP, Parise LV, et al. (2004) Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 104: 3774-3781.
15. Gayen Betal S, Setty BN (2008) Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain. Transl Res 152: 165-177.
16. Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ (2008) Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 112: 3474-3483.
17. Zennadi R, Moeller BJ, Whalen EJ, Batchvarova M, Xu K, et al. (2007) Epinephrine-induced activation of LW-mediated sickle cell adhesion and vasoocclusion in vivo. Blood 110: 2708-2717.
18. Zennadi R, Whalen EJ, Soderblom EJ, Alexander SC, Thompson JW, et al. (2012) Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood 119: 1217-1227.
19. Knight-Madden J, Vergani D, Patey R, Sylvester K, Hussain MJ, et al. (2012) Cytokine levels and profiles in children related to sickle cell disease and asthma status. J Interferon Cytokine Res 32: 1-5.
20. Musa BO, Onyemelukwe GC, Hambolu JO, Mamman AI, Isa AH (2010) Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol 17: 602-608.
21. Qari MH, Dier U, Mousa SA (2012) Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost 18: 195-200.
22. Iverson C, Chapman MS, Clendeninn N, Girardet J, Sheedy B, et al. (2008) The effect of MEK inhibitor RDEA119 on biomarkers in advanced cancer patients in a phase I clinical trial. Molecular Markers (Abstract).
23. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, et al. (2009) RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 69: 6839-6847.
24. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13: 773-781.
25. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, et al. (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17: 989-1000.
26. Unthank JL, Lash JM, Nixon JC, Sidner RA, Bohlen HG (1993) Evaluation of carbocyanine-labeled erythrocytes for microvascular measurements. Microvasc Res 45: 193-210.
27. Algire GH, Legallais FY (1949) Recent developments in the transparentchamber technique as adapted to the mouse. J Natl Cancer Inst 10: 225-253, incl 228 pl.
28. Kalambur VS, Mahaseth H, Bischof JC, Kielbik MC, Welch TE, et al. (2004) Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy. Am J Hematol 77: 117-125.
29. Dewhirst MW, Shan S, Cao Y, Moeller B, Yuan F, et al. (2002) Intravital fluorescence facilitates measurement of multiple physiologic functions and gene expression in tumors of live animals. Dis Markers 18: 293-311.
30. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS (2002) Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A 99: 3047-3051.
31. Dworkis DA, Klings ES, Solovieff N, Li G, Milton JN, et al. (2011) Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol 86: 220-223.
32. Etienne-Julan M, Belloy MS, Decastel M, Dougaparsad S, Ravion S, et al. (2004) Childhood sickle cell crises: clinical severity, inflammatory markers and the role of interleukin-8. Haematologica 89: 863-864.
33. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 96: 2451-2459.
34. Faltynek CR, Schroeder J, Mauvais P, Miller D, Wang S, et al. (1995) Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Biochemistry 34: 12404-12410.
35. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ (1999) Neutrophil activation in sickle cell disease. J Leukoc Biol 66: 411-415.
36. Wun T (2001) The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy. Hematology 5: 403-412.
37. King MR, Bansal D, Kim MB, Sarelius IH (2004) The effect of hematocrit and leukocyte adherence on flow direction in the microcirculation. Ann Biomed Eng 32: 803-814.
38. Baker M, Hafner JW (2012) What is the best pharmacologic treatment for sickle cell disease pain crises? Ann Emerg Med 59: 515-516.
39. Ballas SK, Gupta K, Adams-Graves P (2012) Sickle cell pain: a critical reappraisal. Blood 120: 3647-3656.
40. De Franceschi L, Corrocher R (2004) Established and experimental treatments for sickle cell disease. Haematologica 89: 348-356.
41. Kurantsin-Mills J, Jacobs HM, Klug PP, Lessin LS (1987) Flow dynamics of human sickle erythrocytes in the mesenteric microcirculation of the exchangetransfused rat. Microvasc Res 34: 152-167.
42. Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bourke BN, et al. (2005) Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 111: 3255-3260.
43. Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, et al. (2006) SB- 267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 47: 1600-1605.
44. Fadlon E, Vordermeier S, Pearson TC, Mire-Sluis AR, Dumonde DC, et al. (1998) Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 91: 266-274.
45. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK (1998) Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 92: 3924-3935.
46. Haynes J Jr, Obiako B, Hester RB, Baliga BS, Stevens T (2008) Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol Heart Circ Physiol 294: H379-385.
47. Haynes J Jr, Obiako B, King JA, Hester RB, Ofori-Acquah S (2006) Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells. Am J Physiol Heart Circ Physiol 291: H1679-1685.
48. Hebbel RP, Osarogiagbon R, Kaul D (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11: 129-151.
49. Tomer A, Harker LA, Kasey S, Eckman JR (2001) Thrombogenesis in sickle cell disease. J Lab Clin Med 137: 398-407.
50. Ataga KI, Key NS (2007) Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program: 91-96.
51. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV (2006) Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for plateletmediated inflammation. Arterioscler Thromb Vasc Biol 26: 1626-1631.
52. Lim MY, Ataga KI, Key NS (2013) Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 20: 472-477.